drugset / Trial / NCT03585673
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed. In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2020-03-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel-PM | Unknown | 35 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 120 mg/m2 | Intravenous |